{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"2.6","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"1.2","value":"1.2"},{"groupId":"OG002","lowerLimit":"1.6","upperLimit":"2.3","value":"2.0"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"1.7","value":"1.7"},{"comment":"No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (\\<) 10 millimeter (the sum may not be \"0\" if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was evaluated using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG000","title":"MEDI3617 SINGLE AGENT TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG001","title":"MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL"},{"description":"Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG002","title":"MEDI3617 + BEVACIZUMAB Q2W TOTAL"},{"description":"Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.","id":"OG003","title":"MEDI3617 + PACLITAXEL TOTAL"},{"description":"Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.","id":"OG004","title":"MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received treatment with MEDI3617.","reportingStatus":"POSTED","timeFrame":"Time from the first dose of investigational product until end of study","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}